Valeo Pharma
  • About Us
    • Overview
    • Board of Directors
    • Executive Team
  • Product Portfolio
    • Respiratory / Allergy
    • Ophthalmology
    • Specialty Products
    • Neurology
    • Oncology
  • Partnering
  • Investors
    • Investor Relations
    • Stock information
    • Corporate Presentation
    • Financial Reports
    • Newsroom
    • Webcasts / Events
    • SEDAR documents
  • Careers
  • Contact
  • Français
Select Page
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2022 RESULTS AND HIGHLIGHTS

VALEO PHARMA REPORTS RECORD THIRD QUARTER 2022 RESULTS AND HIGHLIGHTS

by Fred Dumais | Sep 13, 2022 | News Release

Record revenues of $6.1 million in Q3-22, a 27% increase over Q2-22 Record Gross Margins of $2.2 million in Q3-22, up 34% over Q2-22Record YTD-22 revenues of $15.1 million, up 48% over YTD 2021Q4-22 projected revenues to exceed $11 millionXIIDRA®, SIMBRINZA® and...
VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST     

VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST     

by Fred Dumais | Sep 9, 2022 | News Release

MONTREAL, QUEBEC , September 9, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022...
VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM

VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM

by Fred Dumais | Aug 30, 2022 | News Release

Kyle Steiger appointed Senior Vice-President and Chief Commercial OfficerJean-François Fournier appointed new Business Unit Head – Ophthalmology  MONTREAL, QUEBEC, August 30, 2022 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the...
VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM

VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS

by Fred Dumais | Aug 2, 2022 | News Release

Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand into Ophthalmology and Allergy       Licensing transactions to more than double Valeo’s annual...
VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®

VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®

by Fred Dumais | Aug 2, 2022 | News Release

700,000 Canadians suffering from severe allergies Canadian epinephrine auto-injector market exceeds $80M annually ALLERJECT peak sales potential expected to exceed $25M annually MONTREAL, QUEBEC , August 2, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2)...
VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA

VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA

by Fred Dumais | Aug 2, 2022 | News Release

Ophthalmology becomes additional strategic therapeutic area Significant market opportunities with more than 6 million1 Canadians suffering from dry eye disease and 400,0002 Canadians suffering from open-angle glaucoma or ocular hypertension Valeo to start recognizing...
« Older Entries
Next Entries »

Recent News

  • VALEO PHARMA ANNONCE DES REVENUS TRIMESTRIELS ET ANNUELS RECORDS POUR LE QUATRIÈME TRIMESTRE ET L’ANNÉE FINANCIÈRE 2022 January 30, 2023
  • VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022 January 30, 2023
  • VALEO PHARMA ANNONCE LE DÉPÔT D’UNE PRÉSENTATION DE DROGUE NOUVELLE-COVID 19 AUPRÈS DE SANTÉ CANADA POUR SABIZABULIN POUR  LE TRAITEMENT DES PATIENTS HOSPITALISÉS ATTEINTS DE COVID-19 January 26, 2023
  • VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS January 26, 2023

Stay in the loop

I consent to receive news, updates and special offers from Valeo Pharma and it’s affiliates.

Contact us

1-855-694-0151
[email protected]
16667 Hymus Blvd.
Kirkland, QC H9H 4R9

  • About Us
  • Board of Directors
  • Management Team
  • Careers
  • Our Products
  • Business Development
  • Investors Overview
  • Newsroom
  • Stock Information
  • Financial Reports
  • Contact Us
  • Français

© 2022 Valeo Pharma. All rights reserved.

Speak to a professional

I want to speak to:

11 + 3 =